Pazufloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pazufloxacin
Accession Number
DB11774
Type
Small Molecule
Groups
Investigational
Description

Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

Structure
Thumb
Synonyms
Not Available
External IDs
T-3761
Product Ingredients
IngredientUNIICASInChI Key
Pazufloxacin Mesilate2XI226J1HS163680-77-1UDHGFPATQWQARM-FJXQXJEOSA-N
Categories
UNII
4CZ1R38NDI
CAS number
127045-41-4
Weight
Average: 318.304
Monoisotopic: 318.101585134
Chemical Formula
C16H15FN2O4
InChI Key
XAGMUUZPGZWTRP-ZETCQYMHSA-N
InChI
InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
IUPAC Name
(2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
[H][[email protected]]1(C)COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C1(N)CC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Pazufloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pazufloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Pazufloxacin.Experimental, Illicit
AceclofenacAceclofenac may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Pazufloxacin.Approved, Experimental, Investigational
AcenocoumarolPazufloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pazufloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pazufloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Pazufloxacin.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Pazufloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Pazufloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pazufloxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Pazufloxacin.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Pazufloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pazufloxacin.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Pazufloxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Pazufloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Pazufloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Pazufloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Pazufloxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Pazufloxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Pazufloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pazufloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pazufloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Pazufloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Pazufloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Pazufloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pazufloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pazufloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Pazufloxacin.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Pazufloxacin.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Pazufloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Pazufloxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium laevulate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Pazufloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Pazufloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Pazufloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Pazufloxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Pazufloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pazufloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Pazufloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pazufloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Pazufloxacin.Approved
ClorindionePazufloxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Pazufloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Pazufloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pazufloxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pazufloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Pazufloxacin.Experimental
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Pazufloxacin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pazufloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Pazufloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pazufloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Pazufloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Pazufloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pazufloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Pazufloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
DicoumarolPazufloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Pazufloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Pazufloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Pazufloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Pazufloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Pazufloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Pazufloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pazufloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Pazufloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pazufloxacin.Approved
DiphenadionePazufloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamDroxicam may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
DuvelisibDuvelisib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
E-6201E-6201 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Pazufloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Pazufloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Pazufloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Pazufloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Pazufloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Pazufloxacin.Experimental
Ethyl biscoumacetatePazufloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Pazufloxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Pazufloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Pazufloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Pazufloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Pazufloxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Pazufloxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Pazufloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pazufloxacin.Approved
FluindionePazufloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pazufloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Pazufloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Pazufloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Pazufloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pazufloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Pazufloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Pazufloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pazufloxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Pazufloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Pazufloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pazufloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pazufloxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pazufloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Pazufloxacin.Approved, Investigational, Withdrawn
GitoformateGitoformate may decrease the cardiotoxic activities of Pazufloxacin.Experimental
GuacetisalGuacetisal may increase the neuroexcitatory activities of Pazufloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Pazufloxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Pazufloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazufloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Pazufloxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Pazufloxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
IsoxicamIsoxicam may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pazufloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Pazufloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pazufloxacin.Experimental
Lanthanum carbonateThe serum concentration of Pazufloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
LisofyllineLisofylline may increase the neuroexcitatory activities of Pazufloxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Pazufloxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Pazufloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateMagnesium salicylate may increase the neuroexcitatory activities of Pazufloxacin.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Pazufloxacin.Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Pazufloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Pazufloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Pazufloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Pazufloxacin.Investigational, Withdrawn
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pazufloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pazufloxacin.Experimental
MizoribineMizoribine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Pazufloxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pazufloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Pazufloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Pazufloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Pazufloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Pazufloxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Pazufloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Pazufloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Pazufloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Pazufloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Pazufloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Pazufloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Pazufloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Pazufloxacin.Approved, Withdrawn
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pazufloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pazufloxacin.Experimental
PhenindionePazufloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPazufloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pazufloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Pazufloxacin.Experimental
PranoprofenPranoprofen may increase the neuroexcitatory activities of Pazufloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Pazufloxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Pazufloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Pazufloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pazufloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Pazufloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pazufloxacin.Experimental, Investigational
ProbenecidThe serum concentration of Pazufloxacin can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Pazufloxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pazufloxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
QuinaprilThe serum concentration of Pazufloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Pazufloxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Pazufloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational, Withdrawn
SalicylamideSalicylamide may increase the neuroexcitatory activities of Pazufloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Pazufloxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Pazufloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Pazufloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Pazufloxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
Strontium ranelateThe serum concentration of Pazufloxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Pazufloxacin can be decreased when it is combined with Sucralfate.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Pazufloxacin.Approved
SulindacSulindac may increase the neuroexcitatory activities of Pazufloxacin.Approved
SuprofenSuprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Pazufloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Pazufloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Pazufloxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Pazufloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
TioclomarolPazufloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Pazufloxacin.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Pazufloxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pazufloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pazufloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Pazufloxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Pazufloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Pazufloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pazufloxacin.Approved
WarfarinPazufloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
65957
PubChem Substance
347828126
ChemSpider
59360
ChEBI
94700
ChEMBL
CHEMBL240163
ATC Codes
J01MA18 — Pazufloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentOtitis Media (OM)1
2CompletedTreatmentConjunctivitis, Bacterial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.41 mg/mLALOGPS
logP-0.51ALOGPS
logP-1ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)5.59ChemAxon
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.86 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity80.03 m3·mol-1ChemAxon
Polarizability30.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0296000000-cc353f5c3e0ddf62f272

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Haloquinolines / Hydroquinolones / Benzoxazines / Hydroquinolines / Pyridinecarboxylic acids / Alkyl aryl ethers / Aralkylamines / Aryl fluorides / Benzenoids
show 12 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / Haloquinoline / Dihydroquinolone / Benzoxazine / Dihydroquinoline / Pyridine carboxylic acid or derivatives / Pyridine carboxylic acid / Aralkylamine / Alkyl aryl ether
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:47 / Updated on December 01, 2017 17:31